SAMT - ETF AI Analysis
Top Page
Strategas Macro Thematic Opportunities ETF (SAMT)
Rating:56Neutral
Price Target:―
Positive Factors
Strong Year-To-Date Performance
The ETF has delivered strong gains so far this year, suggesting its current strategy has been working well for investors.
Solid Top Holdings
Most of the largest positions, including well-known health care, energy, and consumer companies, have shown strong performance, helping support the fund’s overall returns.
Broad Sector Diversification
The ETF spreads its investments across many sectors such as industrials, consumer defensive, health care, technology, and energy, which helps reduce the impact if any single industry struggles.
Negative Factors
Higher Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which means more of the returns are used to cover fees instead of staying in investors’ pockets.
Recent Short-Term Weakness
The ETF has shown weak performance over the past month, which may signal near-term volatility or a pause in its upward trend.
Heavy U.S. Exposure
With most of its holdings in U.S. companies, the fund offers limited geographic diversification and is more sensitive to changes in the U.S. economy and markets.
SAMT vs. SPDR S&P 500 ETF (SPY)
AUM796.05M
RegionNorth America
Expense Ratio0.66%
Beta0.76
IssuerStrategas
Inception DateJan 26, 2022
Dividend Yield0.65%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume167,880
30 Day Avg. Volume136,759
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
46.72Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering31
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SAMT Summary
Strategas Macro Thematic Opportunities ETF (SAMT) is an actively managed fund that invests in big-picture themes shaping the economy, such as digital transformation, health care innovation, and changes in global supply chains. It doesn’t track a single index, but instead spreads money across many sectors in the U.S., including technology, health care, consumer companies, and energy. Well-known holdings include AbbVie, UnitedHealth, Target, Visa, and Eli Lilly. An investor might choose SAMT for diversified exposure to long-term growth trends, but should remember that its value can go up and down with the market and with shifts in these themes.
How much will it cost me?The Strategas Macro Thematic Opportunities ETF (SAMT) has an expense ratio of 0.65%, meaning you’ll pay $6.50 per year for every $1,000 invested. This is higher than average because it’s actively managed, focusing on identifying and investing in transformative global trends rather than passively tracking an index.
What would affect this ETF?SAMT's focus on transformative global trends, such as digital transformation and sustainable energy, could benefit from technological advancements and increased demand for clean energy solutions, positively impacting its holdings in sectors like Technology and Industrials. However, economic uncertainties, rising interest rates, or regulatory changes in the U.S., where the ETF is geographically concentrated, could negatively affect its performance, especially in sectors like Financials and Consumer Cyclical.
SAMT Top 10 Holdings
SAMT leans into a U.S.-centric mix of consumer, energy, health care, and financial names, with a few standout engines powering returns. Phillips 66 and Chevron have been rising steadily, giving the fund a strong energy tailwind, while Target and Coca-Cola add dependable consumer strength to the story. AbbVie and Johnson & Johnson provide a solid health care backbone with generally steady performance. Amazon, however, has been more mixed lately, losing a bit of steam and modestly dragging on results. Overall, the ETF is diversified across themes rather than dominated by any single sector or stock.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| AbbVie | 3.09% | $24.53M | $462.26B | 7.04% | 66 Neutral | |
| Advanced Micro Devices | 3.03% | $24.01M | $998.68B | 273.00% | 73 Outperform | |
| Phillips 66 | 2.98% | $23.63M | $101.87B | 89.20% | 73 Outperform | |
| Visa | 2.98% | $23.62M | $670.89B | 3.87% | 70 Outperform | |
| Rocket Lab USA | 2.93% | $23.25M | $41.70B | 45.26% | 57 Neutral | |
| Target | 2.93% | $23.22M | $71.18B | 75.05% | 70 Neutral | |
| CrowdStrike Holdings | 2.84% | $22.54M | $271.09B | 114.24% | 67 Neutral | |
| Coca-Cola | 2.77% | $21.98M | $370.36B | 30.23% | 75 Outperform | |
| Eaton | 2.76% | $21.91M | $166.90B | 14.94% | 75 Outperform | |
| Archer Daniels Midland | 2.75% | $21.79M | $38.26B | 34.29% | 64 Neutral |
SAMT Technical Analysis
Negative
―
Price Trends
42.84
Negative
44.06
Negative
42.24
Negative
Market Momentum
-0.28
Negative
40.85
Neutral
15.10
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SAMT, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 42.09, equal to the 50-day MA of 42.84, and equal to the 200-day MA of 42.24, indicating a bearish trend. The MACD of -0.28 indicates Negative momentum. The RSI at 40.85 is Neutral, neither overbought nor oversold. The STOCH value of 15.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SAMT.
SAMT Peer Comparison
Comparison Results
Performance Comparison
SAMT
Strategas Macro Thematic Opportunities ETF
41.81
4.10
10.87%
FEPI
REX FANG & Innovation Equity Premium Income ETF
―
―
―
AIPI
REX AI Equity Premium Income ETF
―
―
―
FFOX
FundX Future Fund Opportunities ETF
―
―
―
DUNK
Dana Unconstrained Equity ETF
―
―
―
GPTY
YieldMax AI & Tech Portfolio Option Income ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents